Inflammasome Therapeutics, Inc.
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $13.2Mattributed |
|---|---|
| Latest round | Funding round, $13.2M, 2026-02-27attributed |
| Founded | unknown |
| Headquarters | Newton, MA |
| Industry | bio |
| Stage | unknown |
| Website | inflam.com |
Inflammasome Therapeutics develops drug therapies that target inflammasome activation to treat degenerative diseases. The company focuses on patients with ophthalmological conditions like geographic atrophy and neurological disorders such as Alzheimer's and ALS. It pursues a single biological pathway across multiple indications rather than disease-specific mechanisms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-02-27 | Funding round | $13.2M | undisclosed |
Detected tech stack
PHP 8.0.30, Apache HTTP Server, Modernizr, jQuery Migrate, WOW, Bootstrap, jquery 1.12.4, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $13.2M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $13.2M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | inflam.com, read 2026-05-05 |
| Description | self-reported | inflam.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $13.2M, 2026-02-27 → Funding round, $13.2M, 2026-02-27, sec-edgar, No document URL on file | Latest round | seed, $13.2M, 2026-02-27 → Funding round, $13.2M, 2026-02-27 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes